Frequencies, response rates, and outcome measures should be reported by genetic group and, if sufficient numbers are available, by specific subsets indicated excluding cases of acute promyelocytic leukemia.

*Includes all AMLs with normal karyotype except for those included in the favorable subgroup; most of these cases are associated with poor prognosis, but they should be reported separately because of the potential different responses to treatment.

†For most abnormalities, adequate numbers were not studied to draw firm conclusions regarding their prognostic significance.

‡Three or more chromosome abnormalities in the absence of one of the WHO designated recurring translocations or inversions, t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23), t(6;9), inv(3)/t(3;3), indicate how many complex karyotype cases have involvement of chromosome arms 5q, 7q, and 17p.